{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T14:00:54Z","timestamp":1788184854387,"version":"build-2803163510"},"reference-count":90,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.intimp.2022.109366","type":"journal-article","created":{"date-parts":[[2023,3,9]],"date-time":"2023-03-09T05:15:00Z","timestamp":1678338900000},"page":"109366","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Erenumab efficacy in migraine headache prophylaxis: A systematic review"],"prefix":"10.1016","volume":"117","author":[{"given":"Mahsa","family":"Bagherzadeh-Fard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Amin Yazdanifar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mona","family":"Sadeghalvad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3836-1827","authenticated-orcid":false,"given":"Nima","family":"Rezaei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.intimp.2022.109366_b0005","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1056\/NEJMra010917","article-title":"Migraine\u2014current understanding and treatment","volume":"346","author":"Goadsby","year":"2002","journal-title":"New England journal of medicine."},{"issue":"9","key":"10.1016\/j.intimp.2022.109366_b0010","first-page":"1495","article-title":"Chronic migraine\u2013evolution of the concept and clinical implications. Headache: The Journal of Head and Face","volume":"58","author":"Medrea","year":"2018","journal-title":"Pain."},{"issue":"1","key":"10.1016\/j.intimp.2022.109366_b0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1468-2982.2008.01709.x","article-title":"Headache Classification Committee of the International Headache Society (IHS) the international classification of headache disorders, asbtracts","volume":"38","author":"Olesen","year":"2018","journal-title":"Cephalalgia."},{"key":"10.1016\/j.intimp.2022.109366_b0020","series-title":"Migraine is first cause of disability in under 50s: will health politicians now take notice?","author":"Steiner","year":"2018"},{"key":"10.1016\/j.intimp.2022.109366_b0025","unstructured":"Society HCSotIH. The international classification of headache disorders. cephalalgia. 2004;24(1):9-160."},{"issue":"2","key":"10.1016\/j.intimp.2022.109366_b0030","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1038\/nm0202-136","article-title":"Intrinsic brain activity triggers trigeminal meningeal afferents in a migraine model","volume":"8","author":"Bolay","year":"2002","journal-title":"Nature medicine."},{"key":"10.1016\/j.intimp.2022.109366_b0035","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/7890461","article-title":"Effects of diet based on IgG elimination combined with probiotics on migraine Plus Irritable bowel Syndrome","volume":"2019","author":"Xie","year":"2019","journal-title":"Pain Research and Management."},{"issue":"11","key":"10.1016\/j.intimp.2022.109366_b0040","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1016\/S1474-4422(18)30322-3","article-title":"Global, regional, and national burden of migraine and tension-type headache, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016","volume":"17","author":"Stovner","year":"2018","journal-title":"The Lancet Neurology."},{"issue":"1","key":"10.1016\/j.intimp.2022.109366_b0045","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s12529-014-9390-x","article-title":"Depression and disability in migraine: The role of pain acceptance and values-based action","volume":"22","author":"Dindo","year":"2015","journal-title":"International journal of behavioral medicine."},{"issue":"sup1","key":"10.1016\/j.intimp.2022.109366_b0050","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.3109\/09638288.2010.511687","article-title":"Functioning and disability in migraine","volume":"32","author":"Leonardi","year":"2010","journal-title":"Disability and rehabilitation."},{"issue":"8","key":"10.1016\/j.intimp.2022.109366_b0055","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1007\/s10194-012-0479-9","article-title":"Depression and risk of transformation of episodic to chronic migraine","volume":"13","author":"Ashina","year":"2012","journal-title":"The journal of headache and pain."},{"issue":"1","key":"10.1016\/j.intimp.2022.109366_b0060","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/0333102417738202","article-title":"Headache classification committee of the international headache society (ihs) the international classification of headache disorders","volume":"38","author":"Arnold","year":"2018","journal-title":"Cephalalgia."},{"key":"10.1016\/j.intimp.2022.109366_b0065","doi-asserted-by":"crossref","DOI":"10.1152\/physrev.00034.2015","article-title":"Pathophysiology of migraine: a disorder of sensory processing","author":"Goadsby","year":"2017","journal-title":"Physiological reviews"},{"issue":"6","key":"10.1016\/j.intimp.2022.109366_b0070","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1517\/14740338.2015.1026325","article-title":"Drug safety in acute migraine treatment","volume":"14","author":"Tajti","year":"2015","journal-title":"Expert opinion on drug safety."},{"issue":"1","key":"10.1016\/j.intimp.2022.109366_b0075","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1517\/14728214.2015.999040","article-title":"Emerging drugs for migraine treatment","volume":"20","author":"Giamberardino","year":"2015","journal-title":"Expert opinion on emerging drugs."},{"issue":"4 Headache","key":"10.1016\/j.intimp.2022.109366_b0080","article-title":"Preventive migraine treatment. Continuum: Lifelong Learning","volume":"21","author":"Silberstein","year":"2015","journal-title":"Neurology."},{"issue":"2","key":"10.1016\/j.intimp.2022.109366_b0085","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1177\/2042098614522683","article-title":"Medication-overuse headache: epidemiology, diagnosis and treatment","volume":"5","author":"Kristoffersen","year":"2014","journal-title":"Therapeutic advances in drug safety."},{"issue":"6","key":"10.1016\/j.intimp.2022.109366_b0090","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.2147\/NDT.S3497","article-title":"Prophylaxis of migraine: general principles and patient acceptance","volume":"4","author":"D\u2019Amico","year":"2008","journal-title":"Neuropsychiatric disease and treatment."},{"issue":"5","key":"10.1016\/j.intimp.2022.109366_b0095","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1517\/14740338.2015.1014797","article-title":"Drug safety and tolerability in prophylactic migraine treatment","volume":"14","author":"V\u00e9csei","year":"2015","journal-title":"Expert opinion on drug safety."},{"key":"10.1016\/j.intimp.2022.109366_b0100","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1146\/annurev-pharmtox-010814-124701","article-title":"Calcitonin gene-related peptide (CGRP): a new target for migraine","volume":"55","author":"Russo","year":"2015","journal-title":"Annual review of pharmacology and toxicology."},{"issue":"6","key":"10.1016\/j.intimp.2022.109366_b0105","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/s41582-018-0003-1","article-title":"CGRP as the target of new migraine therapies\u2014successful translation from bench to clinic","volume":"14","author":"Edvinsson","year":"2018","journal-title":"Nature Reviews Neurology."},{"key":"10.1016\/j.intimp.2022.109366_b0110","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.npep.2018.01.004","article-title":"Calcitonin-gene related peptide is a potent inducer of oedema in rat orofacial tissue","volume":"68","author":"de Queiroz","year":"2018","journal-title":"Neuropeptides."},{"issue":"1","key":"10.1016\/j.intimp.2022.109366_b0115","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s10194-015-0564-y","article-title":"Dural administration of inflammatory soup or Complete Freund\u2019s Adjuvant induces activation and inflammatory response in the rat trigeminal ganglion","volume":"16","author":"Luk\u00e1cs","year":"2015","journal-title":"The journal of headache and pain."},{"issue":"8","key":"10.1016\/j.intimp.2022.109366_b0120","first-page":"1230","article-title":"Calcitonin gene-related peptide (CGRP) and migraine current understanding and state of development. Headache: The Journal of Head and Face","volume":"53","author":"Bigal","year":"2013","journal-title":"Pain."},{"issue":"22","key":"10.1016\/j.intimp.2022.109366_b0125","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1056\/NEJMoa1705848","article-title":"A controlled trial of erenumab for episodic migraine","volume":"377","author":"Goadsby","year":"2017","journal-title":"New England Journal of Medicine."},{"issue":"22","key":"10.1016\/j.intimp.2022.109366_b0130","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1056\/NEJMoa1709038","article-title":"Fremanezumab for the preventive treatment of chronic migraine","volume":"377","author":"Silberstein","year":"2017","journal-title":"New England Journal of Medicine."},{"issue":"9","key":"10.1016\/j.intimp.2022.109366_b0135","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/S1474-4422(14)70128-0","article-title":"Safety and efficacy of LY2951742, a monoclonal antibody to calcitonin gene-related peptide, for the prevention of migraine: a phase 2, randomised, double-blind, placebo-controlled study","volume":"13","author":"Dodick","year":"2014","journal-title":"The Lancet Neurology."},{"issue":"11","key":"10.1016\/j.intimp.2022.109366_b0140","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1016\/S1474-4422(14)70209-1","article-title":"Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trial","volume":"13","author":"Dodick","year":"2014","journal-title":"The Lancet Neurology."},{"issue":"1","key":"10.1016\/j.intimp.2022.109366_b0145","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1124\/jpet.115.227793","article-title":"Pharmacologic characterization of AMG 334, a potent and selective human monoclonal antibody against the calcitonin gene-related peptide receptor","volume":"356","author":"Shi","year":"2016","journal-title":"Journal of Pharmacology and Experimental Therapeutics."},{"key":"10.1016\/j.intimp.2022.109366_b0150","unstructured":"AIMOVIG\u00ae [package insert]. Thousand Oaks, CA: Amgen Inc; 2018.Amgen Inc. https:\/\/www.accessdata.fda.gov\/drugs at fda docs\/label\/2018\/76107 7s000 lbl.pdf. [Last accessed on 2018 Jun 08]."},{"issue":"7","key":"10.1016\/j.intimp.2022.109366_b0155","doi-asserted-by":"crossref","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement","volume":"6","author":"Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group","year":"2009","journal-title":"PLoS Med"},{"issue":"1","key":"10.1016\/j.intimp.2022.109366_b0160","doi-asserted-by":"crossref","DOI":"10.1186\/s10194-021-01313-8","article-title":"Efficacy and safety of erenumab in Japanese migraine patients with prior preventive treatment failure or concomitant preventive treatment: subgroup analyses of a phase 3, randomized trial","volume":"22","author":"Hirata","year":"2021","journal-title":"J Headache Pain."},{"issue":"1","key":"10.1016\/j.intimp.2022.109366_b0165","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/s10194-021-01292-w","article-title":"Reduction in acute migraine-specific and non-specific medication use in patients treated with erenumab: post-hoc analyses of episodic and chronic migraine clinical trials","volume":"22","author":"Tepper","year":"2021","journal-title":"J Headache Pain."},{"issue":"3","key":"10.1016\/j.intimp.2022.109366_b0170","doi-asserted-by":"crossref","DOI":"10.3390\/brainsci11030370","article-title":"Menstrual Headache in Women with Chronic Migraine Treated with Erenumab: An Observational Case Series","volume":"11","author":"Ornello","year":"2021","journal-title":"Brain Sci."},{"issue":"12","key":"10.1016\/j.intimp.2022.109366_b0175","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1212\/WNL.0000000000004391","article-title":"Erenumab (AMG 334) in episodic migraine: interim analysis of an ongoing open-label study","volume":"89","author":"Ashina","year":"2017","journal-title":"Neurology."},{"issue":"1","key":"10.1016\/j.intimp.2022.109366_b0180","doi-asserted-by":"crossref","DOI":"10.1186\/s10194-020-01143-0","article-title":"Multidimensional assessment of the effects of erenumab in chronic migraine patients with previous unsuccessful preventive treatments: A comprehensive real-world experience","volume":"21","author":"Russo","year":"2020","journal-title":"J Headache Pain."},{"key":"10.1016\/j.intimp.2022.109366_b0185","doi-asserted-by":"crossref","DOI":"10.1177\/03331024211010308","article-title":"Erenumab prevents the occurrence of migraine attacks and not just migraine days: Post-hoc analyses of a phase III study","author":"Diener","year":"2021","journal-title":"Cephalalgia."},{"issue":"6","key":"10.1016\/j.intimp.2022.109366_b0190","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S1474-4422(17)30083-2","article-title":"Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial","volume":"16","author":"Tepper","year":"2017","journal-title":"The Lancet Neurology."},{"issue":"22","key":"10.1016\/j.intimp.2022.109366_b0195","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1056\/NEJMoa1705848","article-title":"A controlled trial of erenumab for episodic migraine","volume":"377","author":"Goadsby","year":"2017","journal-title":"New England Journal of Medicine."},{"issue":"1","key":"10.1016\/j.intimp.2022.109366_b0200","doi-asserted-by":"crossref","DOI":"10.1186\/s10194-018-0923-6","article-title":"Early onset of efficacy with erenumab in patients with episodic and chronic migraine","volume":"19","author":"Schwedt","year":"2018","journal-title":"J Headache Pain."},{"issue":"10","key":"10.1016\/j.intimp.2022.109366_b0205","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1111\/head.14233","article-title":"Timing and durability of response to erenumab in patients with episodic migraine","volume":"61","author":"McAllister","year":"2021","journal-title":"Headache."},{"issue":"8","key":"10.1016\/j.intimp.2022.109366_b0210","first-page":"1255","article-title":"Timing and durability of response to erenumab in patients with chronic migraine. Headache: The Journal of Head and Face","volume":"61","author":"Tepper","year":"2021","journal-title":"Pain."},{"issue":"2","key":"10.1016\/j.intimp.2022.109366_b0215","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1001\/jamaneurol.2021.4678","article-title":"Assessment of Erenumab Safety and Efficacy in Patients With Migraine With and Without Aura: A Secondary Analysis of Randomized Clinical Trials","volume":"79","author":"Ashina","year":"2022","journal-title":"JAMA Neurol."},{"issue":"1","key":"10.1016\/j.intimp.2022.109366_b0220","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/s10194-020-01171-w","article-title":"Conversion from chronic to episodic migraine in patients treated with erenumab: real-life data from an Italian region","volume":"21","author":"Ornello","year":"2020","journal-title":"The journal of headache and pain."},{"key":"10.1016\/j.intimp.2022.109366_b0225","article-title":"Reversion from chronic migraine to episodic migraine following treatment with erenumab: Results of a post-hoc analysis of a randomized, 12-week, double-blind study and a 52-week, open-label extension","author":"Lipton","year":"2020","journal-title":"Cephalalgia."},{"issue":"1","key":"10.1016\/j.intimp.2022.109366_b0230","doi-asserted-by":"crossref","DOI":"10.1186\/s10194-020-01151-0","article-title":"Erenumab in highly therapy-refractory migraine patients: First German real-world evidence","volume":"21","author":"Scheffler","year":"2020","journal-title":"J Headache Pain."},{"issue":"1","key":"10.1016\/j.intimp.2022.109366_b0235","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s10194-021-01267-x","article-title":"MAB-MIG: registry of the spanish neurological society of erenumab for migraine prevention","volume":"22","author":"Belv\u00eds","year":"2021","journal-title":"J Headache Pain."},{"key":"10.1016\/j.intimp.2022.109366_b0240","first-page":"12","article-title":"Additive interaction between Onabotulinumtoxin-A and Erenumab in patients with refractory migraine","author":"Silvestro","year":"2021","journal-title":"Front Neurol."},{"key":"10.1016\/j.intimp.2022.109366_b0245","first-page":"1","article-title":"Erenumab and OnabotulinumtoxinA Combination Therapy for the Prevention of Intractable Chronic Migraine without Aura: A Retrospective Analysis","author":"Armanious","year":"2020","journal-title":"J Pain Palliat Care Pharmacother."},{"issue":"1","key":"10.1016\/j.intimp.2022.109366_b0250","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s10194-020-01102-9","article-title":"Real-life data on the efficacy and safety of erenumab in the Abruzzo region, central Italy","volume":"21","author":"Ornello","year":"2020","journal-title":"J Headache Pain."},{"key":"10.1016\/j.intimp.2022.109366_b0255","doi-asserted-by":"crossref","DOI":"10.1007\/s10072-020-05022-z","article-title":"Early outcomes of migraine after erenumab discontinuation: data from a real-life setting","author":"De Matteis","year":"2021","journal-title":"Neurol Sci"},{"issue":"2","key":"10.1016\/j.intimp.2022.109366_b0260","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1002\/ana.410280213","article-title":"Vasoactive peptide release in the extracerebral circulation of humans during migraine headache","volume":"28","author":"Goadsby","year":"1990","journal-title":"Annals of Neurology: Official Journal of the American Neurological Association and the Child Neurology Society."},{"issue":"6","key":"10.1016\/j.intimp.2022.109366_b0265","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s40263-015-0253-z","article-title":"Targeting CGRP: a new era for migraine treatment","volume":"29","author":"Goldberg","year":"2015","journal-title":"CNS drugs."},{"issue":"1","key":"10.1016\/j.intimp.2022.109366_b0270","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s10194-019-1054-4","article-title":"The appropriate dosing of erenumab for migraine prevention after multiple preventive treatment failures: a critical appraisal","volume":"20","author":"Ornello","year":"2019","journal-title":"The journal of headache and pain."},{"issue":"9","key":"10.1016\/j.intimp.2022.109366_b0275","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1007\/s11095-017-2183-6","article-title":"Pharmacokinetic-Pharmacodynamic Relationship of Erenumab (AMG 334) and Capsaicin-Induced Dermal Blood Flow in Healthy and Migraine Subjects","volume":"34","author":"Vu","year":"2017","journal-title":"Pharm Res."},{"issue":"4","key":"10.1016\/j.intimp.2022.109366_b0280","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s40265-019-01069-1","article-title":"Erenumab for preventive treatment of migraine: a systematic review and meta-analysis of efficacy and safety","volume":"79","author":"Lattanzi","year":"2019","journal-title":"Drugs."},{"issue":"52","key":"10.1016\/j.intimp.2022.109366_b0285","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000018483","article-title":"Erenumab safety and efficacy in migraine: A systematic review and meta-analysis of randomized clinical trials","volume":"98","author":"Zhu","year":"2019","journal-title":"Medicine."},{"issue":"10","key":"10.1016\/j.intimp.2022.109366_b0290","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1111\/head.13652","article-title":"A Randomized Phase 2 Study of Erenumab for the Prevention of Episodic Migraine in Japanese Adults","volume":"59","author":"Sakai","year":"2019","journal-title":"Headache."},{"key":"10.1016\/j.intimp.2022.109366_b0295","doi-asserted-by":"crossref","DOI":"10.1111\/head.13929","article-title":"The Spectrum of Response to Erenumab in Patients With Episodic Migraine and Subgroup Analysis of Patients Achieving \u226550%, \u226575%, and 100% Response","author":"Broessner","year":"2020","journal-title":"Headache"},{"issue":"6","key":"10.1016\/j.intimp.2022.109366_b0300","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1177\/0333102418759786","article-title":"ARISE: A Phase 3 randomized trial of erenumab for episodic migraine","volume":"38","author":"Dodick","year":"2018","journal-title":"Cephalalgia."},{"issue":"1","key":"10.1016\/j.intimp.2022.109366_b0305","doi-asserted-by":"crossref","DOI":"10.1186\/s10194-020-01167-6","article-title":"Efficacy and safety of erenumab in women with a history of menstrual migraine","volume":"21","author":"Pavlovic","year":"2020","journal-title":"J Headache Pain."},{"issue":"1","key":"10.1016\/j.intimp.2022.109366_b0310","doi-asserted-by":"crossref","DOI":"10.1186\/s10194-020-01143-0","article-title":"Multidimensional assessment of the effects of erenumab in chronic migraine patients with previous unsuccessful preventive treatments: a comprehensive real-world experience","volume":"21","author":"Russo","year":"2020","journal-title":"The journal of headache and pain."},{"issue":"1","key":"10.1016\/j.intimp.2022.109366_b0315","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1177\/0333102419894559","article-title":"The spectrum of response to erenumab in patients with chronic migraine and subgroup analysis of patients achieving \u226550%, \u226575%, and 100% response","volume":"40","author":"Brandes","year":"2020","journal-title":"Cephalalgia."},{"issue":"6","key":"10.1016\/j.intimp.2022.109366_b0320","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1111\/head.14138","article-title":"Erenumab treatment for migraine prevention in Japanese patients: Efficacy and safety results from a Phase 3, randomized, double-blind, placebo-controlled study","volume":"61","author":"Takeshima","year":"2021","journal-title":"Headache."},{"issue":"5","key":"10.1016\/j.intimp.2022.109366_b0325","doi-asserted-by":"crossref","first-page":"e469","DOI":"10.1212\/WNL.0000000000010019","article-title":"One-year sustained efficacy of erenumab in episodic migraine: Results of the STRIVE study","volume":"95","author":"Goadsby","year":"2020","journal-title":"Neurology."},{"issue":"1","key":"10.1016\/j.intimp.2022.109366_b0330","doi-asserted-by":"crossref","DOI":"10.1186\/s10194-020-01127-0","article-title":"A prospective real-world analysis of erenumab in refractory chronic migraine","volume":"21","author":"Lambru","year":"2020","journal-title":"J Headache Pain."},{"issue":"1","key":"10.1016\/j.intimp.2022.109366_b0335","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s40120-021-00303-x","article-title":"Erenumab Decreases Headache-Related Sick Leave Days and Health Care Visits: A Retrospective Real-World Study in Working Patients with Migraine","volume":"11","author":"Autio","year":"2022","journal-title":"Neurol Ther."},{"issue":"10161","key":"10.1016\/j.intimp.2022.109366_b0340","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1016\/S0140-6736(18)32534-0","article-title":"Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study","volume":"392","author":"Reuter","year":"2018","journal-title":"Lancet."},{"issue":"4","key":"10.1016\/j.intimp.2022.109366_b0345","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/S1474-4422(16)00019-3","article-title":"Safety and efficacy of AMG 334 for prevention of episodic migraine: a randomised, double-blind, placebo-controlled, phase 2 trial","volume":"15","author":"Sun","year":"2016","journal-title":"The Lancet Neurology."},{"key":"10.1016\/j.intimp.2022.109366_b0350","doi-asserted-by":"crossref","DOI":"10.1016\/j.clineuro.2022.107169","article-title":"Effectiveness and safety of erenumab in chronic migraine: A Croatian real-world experience","volume":"214","author":"Mahovi\u0107","year":"2022","journal-title":"Clinical Neurology and Neurosurgery."},{"issue":"2","key":"10.1016\/j.intimp.2022.109366_b0355","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1177\/03331024211053571","article-title":"Erenumab versus topiramate for the prevention of migraine \u2013 a randomised, double-blind, active-controlled phase 4 trial","volume":"42","author":"Reuter","year":"2022","journal-title":"Cephalalgia."},{"key":"10.1016\/j.intimp.2022.109366_b0360","article-title":"Real-life assessment of erenumab in refractory chronic migraine with medication overuse headache","author":"Pensato","year":"2021","journal-title":"Neurol Sci"},{"key":"10.1016\/j.intimp.2022.109366_b0365","article-title":"Erenumab for Migraine Prevention in a 1-Year Compassionate Use Program: Efficacy","volume":"12","author":"Schoenen","year":"2021","journal-title":"Tolerability, and Differences Between Clinical Phenotypes. Front Neurol."},{"issue":"7","key":"10.1016\/j.intimp.2022.109366_b0370","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1177\/0333102419835459","article-title":"Efficacy and safety of erenumab (AMG334) in episodic migraine patients with prior preventive treatment failure: A subgroup analysis of a randomized, double-blind, placebo-controlled study","volume":"39","author":"Goadsby","year":"2019","journal-title":"Cephalalgia."},{"issue":"3","key":"10.1016\/j.intimp.2022.109366_b0375","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1136\/jnnp-2021-327480","article-title":"Two-year efficacy and safety of erenumab in participants with episodic migraine and 2\u20134 prior preventive treatment failures: results from the LIBERTY study","volume":"93","author":"Ferrari","year":"2022","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"10.1016\/j.intimp.2022.109366_b0380","doi-asserted-by":"crossref","DOI":"10.1177\/03331024211010305","article-title":"Efficacy of erenumab in chronic migraine patients with and without ictal allodynia","author":"Lipton","year":"2021","journal-title":"Cephalalgia."},{"issue":"1","key":"10.1016\/j.intimp.2022.109366_b0385","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s40120-021-00245-4","article-title":"Real-World Treatment Profiles, Clinical Outcomes, and Healthcare Resource Utilization of Patients with Migraine Prescribed Erenumab: A Multicenter Chart-Review Study of US Headache Centers","volume":"10","author":"Faust","year":"2021","journal-title":"Neurol Ther."},{"issue":"9","key":"10.1016\/j.intimp.2022.109366_b0390","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1111\/head.13951","article-title":"Real-World Patient Experience With Erenumab for the Preventive Treatment of Migraine","volume":"60","author":"Robblee","year":"2020","journal-title":"Headache."},{"issue":"1","key":"10.1016\/j.intimp.2022.109366_b0395","doi-asserted-by":"crossref","DOI":"10.1186\/s10194-021-01344-1","article-title":"Real-world evidence data on the monoclonal antibody erenumab in migraine prevention: perspectives of treating physicians in Germany","volume":"22","author":"Straube","year":"2021","journal-title":"J Headache Pain."},{"issue":"4","key":"10.1016\/j.intimp.2022.109366_b0400","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1111\/head.14096","article-title":"Long-term efficacy and safety during open-label erenumab treatment in Japanese patients with episodic migraine","volume":"61","author":"Sakai","year":"2021","journal-title":"Headache."},{"issue":"6","key":"10.1016\/j.intimp.2022.109366_b0405","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1177\/0333102420912726","article-title":"Long-term safety and efficacy of erenumab in patients with chronic migraine: Results from a 52-week, open-label extension study","volume":"40","author":"Tepper","year":"2020","journal-title":"Cephalalgia."},{"key":"10.1016\/j.intimp.2022.109366_b0410","doi-asserted-by":"crossref","DOI":"10.1111\/ene.14715","article-title":"Long-term efficacy and safety of erenumab in migraine prevention: Results from a 5-year, open-label treatment phase of a randomized clinical trial","author":"Ashina","year":"2021","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.intimp.2022.109366_b0415","doi-asserted-by":"crossref","DOI":"10.1007\/s10072-021-05105-5","article-title":"Erenumab for the preventive treatment of chronic migraine complicated with medication overuse headache: an observational, retrospective, 12-month real-life study","author":"Cainazzo","year":"2021","journal-title":"Neurol Sci"},{"issue":"10","key":"10.1016\/j.intimp.2022.109366_b0420","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1177\/0333102418788347","article-title":"Efficacy and safety of erenumab (AMG334) in chronic migraine patients with prior preventive treatment failure: A subgroup analysis of a randomized, double-blind, placebo-controlled study","volume":"38","author":"Ashina","year":"2018","journal-title":"Cephalalgia."},{"issue":"20","key":"10.1016\/j.intimp.2022.109366_b0425","doi-asserted-by":"crossref","first-page":"E2309","DOI":"10.1212\/WNL.0000000000007497","article-title":"Erenumab in chronic migraine with medication overuse: Subgroup analysis of a randomized trial","volume":"92","author":"Tepper","year":"2019","journal-title":"Neurology."},{"key":"10.1016\/j.intimp.2022.109366_b0430","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2020.00417","article-title":"Erenumab in Chronic Migraine Patients Who Previously Failed Five First-Line Oral Prophylactics and OnabotulinumtoxinA: A Dual-Center Retrospective Observational Study","volume":"11","author":"Raffaelli","year":"2020","journal-title":"Front Neurol."},{"key":"10.1016\/j.intimp.2022.109366_b0435","doi-asserted-by":"crossref","DOI":"10.1111\/head.14194","article-title":"Long-term (48 weeks) effectiveness, safety, and tolerability of erenumab in the prevention of high-frequency episodic and chronic migraine in a real world: Results of the EARLY 2 study","author":"Barbanti","year":"2021","journal-title":"Headache"},{"issue":"19","key":"10.1016\/j.intimp.2022.109366_b0440","doi-asserted-by":"crossref","DOI":"10.3390\/jcm10194425","article-title":"Real-life analysis with erenumab: First target therapy in the episodic and chronic migraine\u2019s prophylaxis","volume":"10","author":"Maraia","year":"2021","journal-title":"J Clin Med."},{"key":"10.1016\/j.intimp.2022.109366_b0445","doi-asserted-by":"crossref","DOI":"10.1177\/03331024211024160","article-title":"Randomised, controlled trial of erenumab for the prevention of episodic migraine in patients from Asia, the Middle East, and Latin America: The EMPOwER study","author":"Wang","year":"2021","journal-title":"Cephalalgia."},{"key":"10.1016\/j.intimp.2022.109366_b0450","doi-asserted-by":"crossref","unstructured":"Eghtesadi M, Leroux E, Pag\u00e9 G. Real-Life Response to Erenumab in a Therapy-Resistant Case Series of Migraine Patients From the Province of Qu\u00e9bec, Eastern Canada. Clin Drug Investig. 2021.","DOI":"10.1007\/s40261-021-01059-w"}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576922008505?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576922008505?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T17:51:37Z","timestamp":1761587497000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576922008505"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":90,"alternative-id":["S1567576922008505"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2022.109366","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Erenumab efficacy in migraine headache prophylaxis: A systematic review","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2022.109366","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"109366"}}